1
The most serious type of muscle damage, rhabdomyolysis, occurs only rarely but is important to recognise as it may be fatal. 1 Rhabdomyolysis is associated with CK concentrations more than 40 times the upper limit of normal. The patient often has severe muscle pain, stiffness and weakness, with constitutional symptoms of fever and malaise. Their urine may be dark and of small volume, because of myoglobinuria and impaired renal function.
Stopping the drug is the only specific treatment for muscle damage. The symptoms usually resolve rapidly (within a few days to weeks) after withdrawal of statin therapy.
The mechanism of muscle damage is unknown at this stage. Risk factors include high blood concentrations of statins, increasing age, multisystem disease, hypothyroidism, acute illness, major surgery, low body weight and female gender. Drugs that affect the cytochrome P450 system can increase the concentrations of statins that are metabolised by this enzyme system (all statins but pravastatin).
2 Combination therapy with nicotinic acid and gemfibrozil can also result in muscle damage.
The combination of gemfibrozil and cerivastatin was largely responsible for about 100 deaths from complications of rhabdomyolysis. This led to the withdrawal of cerivastatin from world markets in 2001, and increased the attention given to statin-associated muscle damage. 3 Gemfibrozil inhibits a recently reported pathway of hepatic glucuronidation, which appears to be involved in the metabolism of most statins, particularly cerivastatin. 4 Recently, histologically-confirmed muscle damage has been found in four patients with normal CK concentrations. 5 Muscle damage was suspected because of weakness and/or severe myalgia, which responded to statin withdrawal and recurred on statin rechallenge. The histochemical changes observed on muscle biopsy suggested a defect in mitochondrial respiratory chain function. These histological changes resolved three months after statin withdrawal in the three patients who had repeat biopsies. As none of the four patients had high concentrations of statins in their blood, they may have had some kind of increased susceptibility to muscle damage with statin therapy. This finding extends previous observations made in Australia. 6 The prevalence of muscle damage in patients with normal CK concentrations is unknown. The disorder must be seriously considered in any patient taking a statin who complains of muscle aches and pains and/or weakness in spite of normal CK concentrations. A trial of statin withdrawal should be considered.
A plan to manage myopathy in patients on statin therapy has been outlined in the USA. 3 Baseline renal, thyroid and hepatic function tests and CK concentrations are recommended before starting statin therapy. Muscle symptoms should be assessed
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An accurate diagnosis is essential before subjecting patients to immunotherapy. Richard O'Brien reminds us of some of the safety issues. after 6-12 weeks and at each follow-up visit. If muscle symptoms occur the CK should be measured. This advice was published before the finding that muscle damage can occur with a normal CK concentration, so the recommendations regarding statin withdrawal may be too conservative.
Controlled trials have shown that statins improve overall mortality and the incidence of all forms of cardiovascular disease in patients at increased risk of these diseases. Muscle damage must be placed in the context of the recognised benefits of statin therapy. Clinicians should be aware of the need for vigilance in the monitoring of symptoms. Patients should be advised to report any symptoms at the earliest stage in order to prevent the rare, but more serious, muscle complications of statin therapy.
In many cases (perhaps the majority), muscle symptoms will prove to be unrelated to statin therapy. In others, elevated CK concentrations may be the result of exercise or minor muscle damage from trauma. Statin withdrawal and rechallenge may also be subject to a pronounced placebo effect. There is also the potential to further reduce compliance if patients were to believe that any muscle ache or pain they experience may be related to statin therapy. These considerations suggest that the management of statin muscle damage will not be straightforward until there is a specific diagnostic test available. E-mail: admin@medped-aust.com
Asthma delivery devices
Editor, -Thank you for the review of asthma therapy delivery devices (Aust Prescr 2003;26:5-7). This article covered important common sense issues in asthma treatment delivery. As suggested by the author, practical issues of use and patient acceptability dominate the decision between a number of otherwise acceptable drug delivery methods. An additional practical issue, in the experience of many Top End practitioners, is that dry powder devices often do not
